{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"GEHC","limit":50},"count":50,"signals":[{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":21,"context":"review and input from management. Based on results of the assessment, the Compensation Committee concluded that GE HealthCares compensation policies and practices are not reasonably likely to have a material adverse effect on the Company. | | | 48 | GE HEALTHCARE 2026 PROXY STATEMENT | | Compensation Compensation Committee Report The Talent, Culture, and Compensation Committee has reviewed the Compensation Discussion a","filed_date":"2026-03-19","accession":"0001932393-26-000021","full_text":"https://origin.rootz.global/static/filing/0001932393-26-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":17,"context":"| | Proposal | Board VoteRecommendation | | | 1 | Election of the 8 Director Nominees Named in this Proxy Statement for a One-Year Term | | FOR each director nominee | | | | | | | 2 | Approval of Our Named Executive Officers Compensation in an AdvisoryVote | | FOR | | | | | | | 3 | Ratification of the Appointment of Deloitte & Touche LLP as Our Independent Auditor for the Fiscal Year Ending December31, 2026 | | FOR | |","filed_date":"2026-03-19","accession":"0001932393-26-000021","full_text":"https://origin.rootz.global/static/filing/0001932393-26-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"s any acquisition or series of related acquisitions that involves consideration (including non-cash consideration) with a fair market value, as of the closing date thereof, in excess of $250,000,000. Material Adverse Effect means a material adverse effect on (a) the business, property, operations or financial condition of the Borrower and its Subsidiaries taken as a whole or (b) the validity or enforceability of this Ag","filed_date":"2026-02-27","accession":"0001932393-26-000010","full_text":"https://origin.rootz.global/static/filing/0001932393-26-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":14,"context":"that our Chief Operating Decision Maker (which is our Chief Executive Officer) considers to be non-operational, such as Interest and other financial charges net, Benefit (provision) for income taxes, restructuring costs, acquisition and disposition-related benefits (charges), Spin-Off and separation costs, Non-operating benefit (income) costs, gain (loss) on business and asset dispositions, amortization of acquisiti","filed_date":"2026-02-04","accession":"0001932393-26-000007","full_text":"https://origin.rootz.global/static/filing/0001932393-26-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"tements. 50 [Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)  FOREIGN CURRENCY RISK. As a result of our global operations, we generate and incur a significant portion of our revenues and expenses, including those arising from intercompany transactions, in currencies other than the functional currency of our foreign operations creating exposure to foreign currency translation ris","filed_date":"2026-02-04","accession":"0001932393-26-000007","full_text":"https://origin.rootz.global/static/filing/0001932393-26-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":102,"context":"kickback and false claims laws, antitrust and competition laws, privacy and information security laws, and applicable tax laws. Any changes to or violations of these laws and regulations could have a material adverse effect on our business. We are subject to laws and regulations in many jurisdictions governing government contracts, public procurement, and government reimbursements, as to which the failure to comply coul","filed_date":"2026-02-04","accession":"0001932393-26-000007","full_text":"https://origin.rootz.global/static/filing/0001932393-26-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":15,"context":",987 million and included Net income of $2,154 million, adjusted for non-cash items including depreciation and amortization expense of $578 million, the gain on remeasurement of the NMP equity method investment of $97 million, and $647 million in net outflows from changes in assets and liabilities. The changes in assets and liabilities are primarily driven by company-funded benefit payments for postretirement benefit plan","filed_date":"2026-02-04","accession":"0001932393-26-000007","full_text":"https://origin.rootz.global/static/filing/0001932393-26-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":12,"context":"as income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and inve","filed_date":"2025-10-29","accession":"0001932393-25-000053","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":14,"context":"as income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and inve","filed_date":"2025-07-30","accession":"0001932393-25-000049","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":12,"context":"$344 million and included Net income of $1,088 million, adjusted for non-cash items including depreciation and amortization expense of $284 million, the gain on remeasurement of the NMP equity method investment of $97 million, and $930 million in net outflows from changes in assets and liabilities. The changes in assets and liabilities are primarily driven by compensation and benefit payments, company-funded benefit payme","filed_date":"2025-07-30","accession":"0001932393-25-000049","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":14,"context":"as income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and inve","filed_date":"2025-04-30","accession":"0001932393-25-000014","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":12,"context":"25 was $250 million and included Net income of $588 million, adjusted for non-cash items including depreciation and amortization expense of $136 million and gain on remeasurement of NMP equity method investment of $97 million, and $377 million in net outflows from changes in assets and liabilities. The changes in assets and liabilities are primarily driven by compensation and benefit payments, an increase in inventories t","filed_date":"2025-04-30","accession":"0001932393-25-000014","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"nt Summary Company Overview GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and","filed_date":"2025-04-10","accession":"0001628280-25-017240","full_text":"https://origin.rootz.global/static/filing/0001628280-25-017240.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"ll automatically renew for an unlimited number of successive ten-year renewal terms, unless terminated for certain specified events (e.g., a change of control, bankruptcy event, material breaches, or material adverse impact to the GE brand). Real Estate Matters Agreement The Real Estate Matters Agreement with GE governs the allocation and transfer of real estate between GE and us and the colocation of GE and us followin","filed_date":"2025-04-10","accession":"0001628280-25-017240","full_text":"https://origin.rootz.global/static/filing/0001628280-25-017240.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":22,"context":"K, are for the convenience of readers, and information available at or through our website is not a part of, nor is it incorporated by reference in, these documents. | | | | | | | 2 | Approval of Our Named Executive Officers Compensation in an AdvisoryVote | | FOR | | | | | | | 3 | Ratification of the Appointment of Deloitte & Touche LLP as Our Independent Auditor for the Fiscal Year Ending December31, 2025 | | FOR | |","filed_date":"2025-04-10","accession":"0001628280-25-017240","full_text":"https://origin.rootz.global/static/filing/0001628280-25-017240.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"s any acquisition or series of related acquisitions that involves consideration (including non-cash consideration) with a fair market value, as of the closing date thereof, in excess of $250,000,000. Material Adverse Effect means a material adverse effect on (a) the business, property, operations or financial condition of the Borrower and its Subsidiaries taken as a whole or (b) the validity or enforceability of this Ag","filed_date":"2025-03-31","accession":"0001932393-25-000007","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":18,"context":"that our Chief Operating Decision Maker (which is our Chief Executive Officer) considers to be non-operational, such as Interest and other financial charges net, Benefit (provision) for income taxes, restructuring costs, acquisition and disposition-related benefits (charges), Spin-Off and separation costs, Non-operating benefit (income) costs, gain (loss) on business and asset dispositions, amortization of acquisiti","filed_date":"2025-02-13","accession":"0001932393-25-000005","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"(GE HealthCare, the Company, our, or we) is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. We have approximately 53,000 colleagues dedicated to our mission to create a world where healthcare has no limits. We operate at the center of the healthcare ecosystem","filed_date":"2025-02-13","accession":"0001932393-25-000005","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"on about our risk exposures, our use of derivatives, and the effects of this activity on our financial statements. FOREIGN CURRENCY RISK. As a result of our global operations, we generate and incur a significant portion of our revenues and expenses, including those arising from intercompany transactions, in currencies other than the functional currency of our foreign operations creating exposure to foreign currency translation ris","filed_date":"2025-02-13","accession":"0001932393-25-000005","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":104,"context":"alse claims laws, antitrust and competition laws, and stringent privacy laws and information securities regulations, and applicable tax laws and any changes thereto or violations thereof could have a material adverse effect on our business.  We are subject to laws and regulations governing government contracts, public procurement, and government reimbursements in many jurisdictions, as to which the failure to comply cou","filed_date":"2025-02-13","accession":"0001932393-25-000005","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":21,"context":"| | Thomas J. Westrick | 56 | President and CEO, Patient Care Solutions | | The following are brief biographies describing the backgrounds of our executive officers. Peter J. Arduini. Mr. Arduini was appointed as our President and Chief Executive Officer in connection with our Spin-Off from GE. He served as the President and Chief Executive Officer of GEs healthcare business from January 2022 until the Spin-Off. Previously, Mr. Ardu","filed_date":"2025-02-13","accession":"0001932393-25-000005","full_text":"https://origin.rootz.global/static/filing/0001932393-25-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"any acquisition or series of related acquisitions that involves consideration (including non-cash consideration) with a fair market value, as of the closing date thereof, in excess of $250,000,000.  Material Adverse Effect means a material adverse effect on (a) the business, property, operations or financial condition of the Borrower and its Subsidiaries taken as a whole or (b) the validity or enforceability of this Ag","filed_date":"2024-12-12","accession":"0001193125-24-277089","full_text":"https://origin.rootz.global/static/filing/0001193125-24-277089.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"as income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and inve","filed_date":"2024-10-30","accession":"0001932393-24-000050","full_text":"https://origin.rootz.global/static/filing/0001932393-24-000050.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":12,"context":"as Income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and inve","filed_date":"2024-07-31","accession":"0001932393-24-000044","full_text":"https://origin.rootz.global/static/filing/0001932393-24-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":11,"context":"as Income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and inve","filed_date":"2024-04-30","accession":"0001932393-24-000034","full_text":"https://origin.rootz.global/static/filing/0001932393-24-000034.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"000193239324000022/) **Origin leaf:** bb49f24bc65602ba9d5ec11ae9ecda3c7dc39a5bc7c36208710b9809e61bf68a **Words:** 47,679 **Logo:** https://api.massive.com/v1/reference/company-branding/Z2VoZWFsdGhjYXJlLmNvbQ/images/2025-04-04_logo.svg --- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of","filed_date":"2024-04-04","accession":"0001932393-24-000022","full_text":"https://origin.rootz.global/static/filing/0001932393-24-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ll automatically renew for an unlimited number of successive ten-year renewal terms, unless terminated for certain specified events (e.g., a change of control, bankruptcy event, material breaches, or material adverse impact to the GE brand). Real Estate Matters Agreement The Real Estate Matters Agreement with GE governs the allocation and transfer of real estate between GE and us and the colocation of GE and us followin","filed_date":"2024-04-04","accession":"0001932393-24-000022","full_text":"https://origin.rootz.global/static/filing/0001932393-24-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":21,"context":"K, are for the convenience of readers, and information available at or through our website is not a part of, nor is it incorporated by reference in, these documents. | | | | | | | 2 | Approval of Our Named Executive Officers Compensation in an AdvisoryVote | | FOR | | | | | | | 3 | Ratification of the Appointment of Deloitte & Touche LLP as Our Independent Auditor for the Fiscal Year Ending December31, 2024 | | FOR | |","filed_date":"2024-04-04","accession":"0001932393-24-000022","full_text":"https://origin.rootz.global/static/filing/0001932393-24-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":13,"context":"that our Chief Operating Decision Maker (which is our Chief Executive Officer) considers to be non-operational, such as Interest and other financial charges net, Benefit (provision) for income taxes, Restructuring costs, Acquisition and disposition-related benefits (charges), Spin-Off and separation costs, Non-operating benefit (income) costs, Gain (loss) on business and asset dispositions, Amortization of acquisiti","filed_date":"2024-02-06","accession":"0001932393-24-000013","full_text":"https://origin.rootz.global/static/filing/0001932393-24-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"into derivative contracts to the extent they meet the objectives described above, and not for speculative purposes. FOREIGN CURRENCY RISK.As a result of our global operations, we generate and incur a significant portion of our revenues and expenses, including those arising from intercompany transactions, in currencies other than the functional currency of our foreign operations creating exposure to foreign currency translation ris","filed_date":"2024-02-06","accession":"0001932393-24-000013","full_text":"https://origin.rootz.global/static/filing/0001932393-24-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":114,"context":"unions, and other employee representatives it could adversely affect our business. Public health crises, epidemics, and pandemics, such as the COVID-19 pandemic, have had and in the future may have a material adverse impact on our business, as well as on the operations and financial performance of some of the customers and suppliers in industries that we serve. Our research and development efforts may not succeed in dev","filed_date":"2024-02-06","accession":"0001932393-24-000013","full_text":"https://origin.rootz.global/static/filing/0001932393-24-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":21,"context":"ice Officer | | | Thomas J. Westrick | 55 | CEO, Patient Care Solutions | | The following are brief biographies describing the backgrounds of our executive officers. Peter J. Arduini. Mr. Arduini was appointed as our President and Chief Executive Officer in connection with our Spin-Off from GE. He served as the President and Chief Executive Officer of GEs healthcare business from January 2022 until the Spin-Off. Previously, Mr. Ardu","filed_date":"2024-02-06","accession":"0001932393-24-000013","full_text":"https://origin.rootz.global/static/filing/0001932393-24-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"s any acquisition or series of related acquisitions that involves consideration (including non-cash consideration) with a fair market value, as of the closing date thereof, in excess of $250,000,000. Material Adverse Effect means a material adverse effect on (a) the business, property, operations or financial condition of the Borrower and its Subsidiaries taken as a whole or (b) the validity or enforceability of this Ag","filed_date":"2023-12-15","accession":"0001932393-23-000133","full_text":"https://origin.rootz.global/static/filing/0001932393-23-000133.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":11,"context":"ore income taxes in our Condensed Consolidated and Combined Statements of Income excluding the impact of the following: Interest and other financial charges net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition related benefits (charges), gain (loss) of business and asset dispositions, spin-off and separation costs, amortization of acquisition-related intangible assets, and inve","filed_date":"2023-10-31","accession":"0001932393-23-000125","full_text":"https://origin.rootz.global/static/filing/0001932393-23-000125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":11,"context":"uing operations before income taxes in our Condensed Consolidated and Combined Statements of Income less the following: Interest and other financial charges net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gains and losses of business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and","filed_date":"2023-07-25","accession":"0001932393-23-000112","full_text":"https://origin.rootz.global/static/filing/0001932393-23-000112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":11,"context":"gment EBIT is calculated as Income from continuing operations less the following: Benefit (provision) for income taxes, Interest and other financial charges net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gains and losses on business dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and investmen","filed_date":"2023-04-25","accession":"0001932393-23-000087","full_text":"https://origin.rootz.global/static/filing/0001932393-23-000087.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":21,"context":"e for the convenience of readers, and information available at or through our website is not a part of, nor is it incorporated by reference in, thesedocuments. | | | | | | | | | | 2 | Approval of our named executive officers compensation in an advisory vote | | | | | | | | | | | | | | | | | | 3 | Approval of the frequency of future advisory votes on named executive officers compensation in an advisoryvote | | | | | | |","filed_date":"2023-04-05","accession":"0001932393-23-000070","full_text":"https://origin.rootz.global/static/filing/0001932393-23-000070.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":13,"context":"and certain transactions or adjustments that our Chief Operating Decision Maker (which is our Chief Executive Officer) considers to be non-operational, such as interest expenses, income tax expenses, restructuring costs, acquisition and disposition related charges (benefits), Spin-Off and separation costs, Non-operating benefit (income) costs, gain/loss of business dispositions/divestments, amortization of acquisiti","filed_date":"2023-02-15","accession":"0001932393-23-000025","full_text":"https://origin.rootz.global/static/filing/0001932393-23-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"extent they meet the objective described above, and we do not use derivatives for trading or speculative purpose.  FOREIGN CURRENCY RISK. As a result of our global operations, we generate and incur a significant portion of our revenues and expenses in currencies other than the U.S. dollar. Such principal currencies include the Euro, the Chinese Yuan, the Japanese Yen, the Norwegian Krone, and the British Pound Sterling, among othe","filed_date":"2023-02-15","accession":"0001932393-23-000025","full_text":"https://origin.rootz.global/static/filing/0001932393-23-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":86,"context":"ns of our customers or third parties that are outside of our control. Our business operations are subject to extensive laws and regulations, and any changes thereto or violations thereof could have a material adverse effect on our business.  Increasing attention to ESG matters, including environmental, health, and safety (EH&S) matters, may impose additional costs on our business and expose us to new risks. We incurred","filed_date":"2023-02-15","accession":"0001932393-23-000025","full_text":"https://origin.rootz.global/static/filing/0001932393-23-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":32,"context":"ce Officer | | | Thomas J. Westrick | 54 | CEO, Patient Care Solutions | | The following are brief biographies describing the backgrounds of our executive officers.  Peter J. Arduini. Mr. Arduini was appointed as our President and Chief Executive Officer in connection with our Spin-Off from GE. He served as the President and Chief Executive Officer of GEs healthcare business from January 2022 until January 2023. Previously, Mr. Ardu","filed_date":"2023-02-15","accession":"0001932393-23-000025","full_text":"https://origin.rootz.global/static/filing/0001932393-23-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":15,"context":"erating benefit (income) costs (3) Provision (benefit) for income taxes (4) Income (loss) from discontinued operations, net of taxes (5) Net (income) loss attributable to noncontrolling interests (6) restructuring costs (7) acquisition, disposition related charges (benefits) (8) Spin-Off and separation costs (9) (gain)loss of business dispositionsdivestments (10) amortization of acquisition related intangible assets","filed_date":"2023-01-30","accession":"0001932393-23-000007","full_text":"https://origin.rootz.global/static/filing/0001932393-23-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"restructuring","strength":100,"match_count":25,"context":"|  |  |  |  |  |  |  |  |  |  |  | | |  EBIT* |  |  $ |  1,760 |  |  |  $ |  2,756 |  |  |  $ |  1,808 |  |  |  $ |  2,156 |  |  |  $ |  2,918 |  |  |  $ |  2,781 |  |  |  $ |  2,188 |  | | |  Add: Restructuring costs(a) |  |  |  110 |  |  |  |  155 |  |  |  |  110 |  |  |  |  127 |  |  |  |  155 |  |  |  |  134 |  |  |  |  160 |  | | |  Add: Acquisition and disposition related charges (benefits)(b) |  |  |  (20 |","filed_date":"2022-12-08","accession":"0001193125-22-301053","full_text":"https://origin.rootz.global/static/filing/0001193125-22-301053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"backlog_growth","strength":100,"match_count":10,"context":"r unsatisfied (or partially unsatisfied) performance obligations was $14,571 million. We expect to recognize revenue as we satisfy our remaining performance obligations as follows: 1) product-related remaining performance obligation of $4,543 million of which 97% is expected to be recognized within two years, and the remaining thereafter; and 2) services-related remaining performance obligations of $10,028 million of which 64% and 96","filed_date":"2022-12-08","accession":"0001193125-22-301053","full_text":"https://origin.rootz.global/static/filing/0001193125-22-301053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"platform_shift","strength":100,"match_count":22,"context":"by population growth, an increasing proportion of the population over the age of 65, and the increasing prevalence and treatment of chronic diseases. | | |  |  |  |  Improving access to healthcare in emerging markets. The growing middle class in many of these markets is helping to drive both government and private sector investment in healthcare systems and medical technology. | | |  * |  Non-GAAP financial meas","filed_date":"2022-12-08","accession":"0001193125-22-301053","full_text":"https://origin.rootz.global/static/filing/0001193125-22-301053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"cribed above, and we do not use derivatives for trading or speculative purpose.  165  [Table of Contents](#toc) **Foreign Exchange Risk** As a result of our global operations, we generate and incur a significant portion of our revenues and expenses in currencies other than the U.S. Dollar. Such principal currencies include the Euro, the Chinese Yuan, the Japanese Yen, the Norwegian Krone, and the British Pound Sterling, among othe","filed_date":"2022-12-08","accession":"0001193125-22-301053","full_text":"https://origin.rootz.global/static/filing/0001193125-22-301053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"margin_pressure","strength":100,"match_count":10,"context":"iring us to lower prices or resulting in a loss of market share.** Healthcare markets are characterized by rapidly evolving technology, frequent introduction of new products, intense competition, and pricing pressure. We face substantial competition from international and domestic companies of all sizes; these competitors often differ across our businesses. Competition is primarily focused on cost effectiveness,","filed_date":"2022-12-08","accession":"0001193125-22-301053","full_text":"https://origin.rootz.global/static/filing/0001193125-22-301053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"growth_inflection","strength":100,"match_count":26,"context":"due to an unfavorable impact from foreign currency changes, partially offset by continued growth in our service revenues.  The segment revenue performance was as follows:  |  |  |  |  Imaging segment revenue increased $165 million, or 7% as reported and 12% organically*. This was mainly attributable to strong growth in MR and Image-Guided Therapies products due to improved supply chain performance in fulfilling customer demand","filed_date":"2022-12-08","accession":"0001193125-22-301053","full_text":"https://origin.rootz.global/static/filing/0001193125-22-301053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"risk_factor","strength":100,"match_count":90,"context":"hat are outside of our control. | | 13  Table of Contents |  |  |  |  Our business operations are subject to extensive laws and regulations, and any changes thereto or violations thereof could have a material adverse effect on our business. | | |  |  |  |  Increasing attention to environmental, social, and governance (ESG) matters, including environmental, health, and safety (EH&S) matters, may impose additional costs o","filed_date":"2022-12-08","accession":"0001193125-22-301053","full_text":"https://origin.rootz.global/static/filing/0001193125-22-301053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GEHC","company":"GE HealthCare Technologies Inc.","exchange":"Nasdaq","sector":"X-Ray Apparatus & Tubes & Related Irradiation Apparatus","signal_type":"strategic_event","strength":100,"match_count":118,"context":"r R&D efforts focus on creating new products and solutions, developing new applications for products, and enhancing our existing products to help improve outcomes for customers and their patients. We invested $816 million in R&D in 2021, a 1% increase from 2020. We conduct global R&D efforts in 18 countries that include both developed and emerging markets. As of 2021, we employ over 9,700 engineers and scientists, inc","filed_date":"2022-12-08","accession":"0001193125-22-301053","full_text":"https://origin.rootz.global/static/filing/0001193125-22-301053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"6f243005ca80188b11c404cfcc83187477ea80f1ac0224425cba6c6bcdba4727","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"221aedf9b767394b3e995e68530455d6e1df6261ca1ca05aaa4ff9904f2bffcb","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":47,"hourly_limit":500,"remaining":453,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}